Physician profile
Ramzi E Aboujaoude
NPI 1093911802
$9,809.88
in general payments reported to CMS, 2019-2025
28 companies · $784 in 2025
The $784 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,833 · 2020: $502 · 2021: $2,044 · 2022: $1,177 · 2023: $1,324 · 2024: $1,145 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095 · Education: $99.99 · Gift: $58.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,095.40 |
| Education | $99.99 |
| Gift | $58.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $3,469.91 | 2019-2024 | Desara |
| Intuitive Surgical, INC. | $1,857.01 | 2019-2022 | |
| Boston Scientific Corporation | $1,117.27 | 2019-2025 | Upsylon |
| Axonics, INC. | $765.19 | 2022-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $509.81 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $457.34 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $302.88 | 2019-2025 | Botox |
| Medtronic, INC. | $297.88 | 2022-2024 | Interstim |
| Coopersurgical, INC. | $168.70 | 2019-2025 | Paragard T 380a |
| Medtronic USA, INC. | $166.13 | 2019-2020 | |
| Bluewind Medical | $115.31 | 2024 | Revi |
| Allergan, INC. | $96.09 | 2019-2021 | |
| Avion Pharmaceuticals | $71.17 | 2019 | |
| Conmed Corporation | $66.67 | 2019 | |
| Mayne Pharma Commercial LLC | $63.91 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $43.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.59 | 2025 | Vpriv |
| Biogen, INC. | $36.80 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $31.95 | 2020-2021 | |
| Daiichi Sankyo INC. | $26.88 | 2024 | Injectafer |
| Mimedx Group, INC. | $25.78 | 2024 | |
| Hologic Sales and Service, LLC | $19.11 | 2024 | Aptima |
| Pfizer INC. | $16.47 | 2025 | |
| Agile Therapeutics, INC. | $12.05 | 2021 | |
| Therapeuticsmd, INC. | $12.02 | 2020 | |
| Lupin INC. | $11.52 | 2019 | |
| Amgen INC. | $11.41 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramzi Aboujaoude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.